Bio-Techne TECH Business Segments
| Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Business | ||||||
| Diagnostics And Spatial Biology | $85.59M+5.4% | $81.18M+2.2% | $79.46M-11.4% | $89.71M+0.5% | $89.23M+6.1% | |
| Protein Sciences | $226.15M+5.1% | $215.08M+6.4% | $202.19M-10.7% | $226.47M-0.5% | $227.69M+7.6% | |
| Revenue by Product | ||||||
| Consumables | $257.34M+9.3% | $235.44M+1.7% | $231.6M-8.4% | $252.94M-1.9% | $257.79M+11.7% | |
| Instruments | $27.66M-6.6% | $29.61M+35.6% | $21.83M-24.5% | $28.9M+10.7% | $26.11M-15.4% | |
| Royalty | $4.97M-41.7% | $8.51M+50.8% | $5.65M+2.6% | $5.51M+9.2% | $5.04M-37.8% | |
| Service | $21.45M-3.9% | $22.32M-18.8% | $27.48M-7.2% | $29.62M+8.7% | $27.25M-0.4% | |
| Revenue by Geography | ||||||
| APAC Excluding Greater China | $21.82M-4.1% | $22.74M+18.8% | $19.15M+1.4% | $18.89M-11.1% | $21.25M+11.8% | |
| CN | $26.01M-1.3% | $26.35M+6.3% | $24.79M-7.9% | $26.91M+9.9% | $24.48M-1.1% | |
| EMEA Excluding UK | $73.45M-2.5% | $75.35M+15.7% | $65.13M-7.4% | $70.35M+5.8% | $66.5M-5.5% | |
| GB | $14.89M+8.5% | $13.73M+4.0% | $13.21M-10.7% | $14.79M+15.1% | $12.85M-3.0% | |
| Rest Of World | $7.77M-30.3% | $11.15M+23.2% | $9.05M-6.2% | $9.65M+5.1% | $9.18M-5.6% | |
| US | $167.48M+14.3% | $146.56M-5.6% | $155.24M-12.0% | $176.39M-3.0% | $181.92M+13.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Bio-Techne break its business down?
- Bio-Techne (TECH) reports revenue by business across 2 parts — Diagnostics And Spatial Biology and Protein Sciences. Each is extracted from the segment footnotes and tracked over time.
- Where does Bio-Techne's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Bio-Techne's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
